• FirefoxInstall the new Firefox »
  •  Dow Down1.02% Nasdaq Down0.76%

    Amicus Therapeutics, Inc. (FOLD)

    8.41 Down 0.24(2.77%) 11:34AM EST - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Amicus Therapeutics, Inc.
    1 Cedar Brook Drive
    Cranbury, NJ 08512
    United States - Map
    Phone: 609-662-2000
    Fax: 609-662-2001
    Website: http://www.amicustherapeutics.com

    Index Membership:N/A
    Full Time Employees:92

    Business Summary 

    Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. It develops enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs), including Fabry disease, Pompe disease, and Mucopolysaccharoidosis Type I (MPS I). The company also develops novel small molecules as monotherapy treatments for Fabry disease and Parkinson's disease. Its chaperone-advanced replacement therapy program is used to develop next-generation ERTs by co-formulating therapeutic enzymes with proprietary pharmacological chaperones. The company’s lead programs include the small molecule pharmacological chaperones, migalastat HCl as a monotherapy that is in Phase III global registration studies for Fabry patients with genetic mutations; and AT2220 (duvoglustat HCl), which has completed Phase II safety used for the treatment of Pompe disease. Its products also comprise AT-B200, a proprietary recombinant human acid-alpha glucosidase that is in late preclinical development for Pompe disease; and AT3375 for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Amicus Therapeutics, Inc.

    Corporate Governance 
    Amicus Therapeutics, Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 10. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. John F. Crowley , 48
    Chairman and Chief Exec. Officer
    Mr. Bradley L. Campbell , 39
    Pres and Chief Operating Officer
    Mr. William D. Baird III, 43
    Chief Financial Officer and Sec.
    Ms. Daphne E. Quimi , 49
    Principal Accounting Officer, VP of Fin. and Corp. Controller
    Mr. Enrique Dilone Ph.D., RAC, 48
    VP of Technical Operations
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders